Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TradeUP Acquisition
Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Estrella Immunopharma is a preclinical biotech company developing CD19- and CD22-targeted T cell therapies for blood cancers and solid tumors, aiming to reduce the risk of Cytokine Release Syndrome compared to traditional CAR-T therapies. The company is a result of a business combination between TradeUP Acquisition Corp. (a special purpose acquisition company, or SPAC) and Estrella Biopharma, Inc., and began trading on NASDAQ as ESLA and ESLAW in October 2023. Its lead programs leverage the ARTEMIS platform, licensed from Eureka Therapeutics, and the company is collaborating with Imugene on a 'mark and kill' strategy for solid tumors. The company does not yet have clinical data; all programs are in preclinical development.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyT cell receptor engineered T cell therapy
- Industry
- Biotech
02
Partnerships
Eureka Therapeutics (platform licensing)Imugene (collaboration on CF33-CD19t for solid tumor treatment)
Beyond the preview
Go deeper on TradeUP Acquisition.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TradeUP Acquisition.